IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+16.64%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$762M
AUM Growth
+$762M
(+58%)
Cap. Flow
+$253M
Cap. Flow
% of AUM
33.18%
Top 10 Holdings %
Top 10 Hldgs %
36.2%
Holding
102
New
30
Increased
25
Reduced
12
Closed
27
Top Buys
| 1 |
Cigna
CI
|
$50.5M |
| 2 |
Zimmer Biomet
ZBH
|
$43.7M |
| 3 |
McKesson
MCK
|
$30.8M |
| 4 |
Tenet Healthcare
THC
|
$18.9M |
| 5 |
Boston Scientific
BSX
|
$17M |
Top Sells
| 1 |
Stryker
SYK
|
$14.3M |
| 2 |
Teleflex
TFX
|
$11.7M |
| 3 |
Cardinal Health
CAH
|
$11.5M |
| 4 |
Biogen
BIIB
|
$11.1M |
| 5 |
uniQure
QURE
|
$10.1M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Johnson & Johnson
JNJ
$429B
| $11.9M | 1.48% |
+72,000
| New | +$11.9M |
|
27
Viking Therapeutics
VKTX
$3.02B
| $11.8M | 1.47% |
730,000
+2,900
| +0.4% | +$47K |
|
28
Ventyx Biosciences
VTYX
$184M
| $11.5M | 1.42% |
350,000
+60,000
| +21% | +$1.97M |
|
29
Surgery Partners
SGRY
$2.89B
| $11.2M | 1.39% |
250,000
+128,000
| +105% | +$5.76M |
|
30
Novartis
NVS
$248B
| $10.4M | 1.29% |
+103,000
| New | +$10.4M |
|
31
Replimune Group
REPL
$460M
| $10.3M | 1.28% |
445,000
+50,000
| +13% | +$1.16M |
|
32
Penumbra
PEN
$10.5B
| $10.3M | 1.28% |
30,000
-5,000
| -14% | -$1.72M |
|
33
Alnylam Pharmaceuticals
ALNY
$58.6B
| $9.88M | 1.22% |
52,000
+32,000
| +160% | +$6.08M |
|
34
Revolution Medicines
RVMD
$7.43B
| $9.52M | 1.18% |
356,000
+11,000
| +3% | +$294K |
|
|
NARI
35
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $9.01M | 1.12% |
155,000
+55,000
| +55% | +$3.2M |
|
|
ITCI
36
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $8.99M | 1.11% |
+142,000
| New | +$8.99M |
|
37
Alkermes
ALKS
$4.95B
| $8.89M | 1.1% |
284,000
+105,000
| +59% | +$3.29M |
|
38
Relay Therapeutics
RLAY
$709M
| $8.79M | 1.09% |
700,000
-70,000
| -9% | -$879K |
|
39
Intellia Therapeutics
NTLA
$1.26B
| $8.4M | 1.04% |
+206,000
| New | +$8.4M |
|
40
Exact Sciences
EXAS
$9.33B
| $8.26M | 1.02% |
88,000
-74,000
| -46% | -$6.95M |
|
41
Teva Pharmaceuticals
TEVA
$21.5B
| $7.53M | 0.93% |
+1,000,000
| New | +$7.53M |
|
42
Krystal Biotech
KRYS
$4.35B
| $7.28M | 0.9% |
62,000
-23,000
| -27% | -$2.7M |
|
43
PTC Therapeutics
PTCT
$4.41B
| $7.08M | 0.88% |
174,000
-4,000
| -2% | -$163K |
|
44
Lifestance Health
LFST
$2.14B
| $7.06M | 0.87% |
773,000
+64,000
| +9% | +$584K |
|
45
Medtronic
MDT
$118B
| $7.05M | 0.87% |
+80,000
| New | +$7.05M |
|
46
Apellis Pharmaceuticals
APLS
$3.51B
| $6.56M | 0.81% |
+72,000
| New | +$6.56M |
|
|
RVNC
47
DELISTED
Revance Therapeutics, Inc.
RVNC
| $6.33M | 0.78% |
250,000
| – | – |
|
48
TG Therapeutics
TGTX
$5.03B
| $6.21M | 0.77% |
+250,000
| New | +$6.21M |
|
49
SI-BONE Inc
SIBN
$700M
| $6.12M | 0.76% |
+227,000
| New | +$6.12M |
|
50
CRISPR Therapeutics
CRSP
$4.82B
| $5.61M | 0.7% |
100,000
| – | – |
|